Kevin Kalinsky

Dec 11, 2024 | onclive.com | Kevin Kalinsky |Virginia Kaklamani

Opinion Video December 11, 2024 Author(s): , Panelists discuss how the NCCN guidelines for risk stratification in HR+/HER2– early-stage breast cancer (eBC) guide clinical decision-making, exploring real-world adherence to these guidelines, the complexity of risk stratification in various clinical scenarios, and the role of clinical factors, biomarkers, and advanced testing methodologies (including RSClin N+, next-generation sequencing [NGS], fluorescence in situ hybridization [FISH],...

Dec 4, 2024 | onclive.com | Kevin Kalinsky |Virginia Kaklamani

Opinion Video December 4, 2024 Author(s): , Panelists discuss how the NCCN guidelines for risk stratification in HR+/HER2– early-stage breast cancer (eBC) guide clinical decision-making, exploring real-world adherence to these guidelines, the complexity of risk stratification in various clinical scenarios, and the role of clinical factors, biomarkers, and advanced testing methodologies (including RSClin N+, next-generation sequencing [NGS], fluorescence in situ hybridization [FISH],...

Dec 4, 2024 | onclive.com | Kevin Kalinsky |Virginia Kaklamani

OpinionVideoDecember 4, 2024Author(s):,Panelists discuss how HR+/HER2– early-stage breast cancer (eBC) is characterized by hormone receptor–positive, HER2-negative tumors, focusing on unmet patient needs, the goals of treatment in this setting, and the critical timing for discussing recurrence risk with patients. Video content above is prompted by the following:Please provide an overview of HR+/HER2– early-stage breast cancer (eBC).

Dec 3, 2024 | onclive.com | Kevin Kalinsky

CommentaryVideoDecember 3, 2024Author(s):Kevin Kalinsky, MD, MS, discusses outcomes of the phase 3 postMONARCH study in hormone receptor–positive, HER2-negative advanced breast cancer.

Nov 22, 2024 | onclive.com | Kevin Kalinsky

CommentaryVideoNovember 22, 2024Author(s):Fact checked by:,Kevin Kalinsky, MD, MS, discusses the phase 3 DESTINY-Breast06 trial evaluating trastuzumab deruxtecan in HER2-expressing breast cancer.